Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q4 2017 · 10-K
Revenue$59.59M$59.59M+56.1% vs Q4 2016 Net Income-$42.48M-$42.48MN/M vs Q4 2016 EPS Diluted-$2.02-$2.02N/M vs Q4 2016 Operating Incomederived$28,352,000+46.5% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Operating Cash Flowderived$31,310,000+67.2% Free Cash Flowderived$29,374,000+57.4% Margins · derivedOperating margin47.6%−3.1 pt vs Q4 2016
Net margin-71.3%−63.1 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 1, 2018 · 60 d after period end